CONTRAINDICATED MEDICATIONS AND REGIMENS FOR HIV INFECTED PATIENTS (09HC04)

Home | Page 1 | Page 2 | Page 3 | References | Cases | Post-test

REFERENCES

1. Center for Disease Control. Epidemiology of HIV/AIDS – United States 1981-2005. Morb Mortal Wkly Rev. 2006;55:589-92.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services. October 10, 2006; 1-113. Accessed February 14, 2007. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf
3. Macher A, Thomas D, Paul S. Contraindicated Antiretroviral Drug Regimens. New Jersey Medicine. 2003;100 (suppl):41-43.
4. Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis, 2001.33(11):1931-7.
5. Coghlan ME, Sommadossi JP, Jhala NC, et al. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin Infect Dis, 2001. 33(11):1914-21.
6. Food and Drug Administration. FDA/Bristol Myers Squibb issues caution for HIV combination therapy with Zerit and Videx in pregnant women. Rockville, MD: U.S. Department of Health and Human Services; Jan 5, 2001. Talk Paper T01-02.
7. Fundaro C, Genovese O, Rendeli C, et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS. 2003:16:299-300.
8. Product Information Sustiva®. Bristol Meyers Squibb. 2006
9. Recommendations for the use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. October 12, 2006. Available at: http://www.aidsinfo.nih.gov. Accessed February 14, 2007.
10. Delfraissy JF, Flandre P, Delaugerre C, et al. 48 week analysis of LPV/r monotherapy compared to LPV/r + AZT/3TC in antiretroviral-naive patients: MONARK trial. XVI International AIDS Conference; August 13-18,2006; Toronto, Canada. Abstract THLB0202.
11. Swindells S, DiRenzo AG, Wilkin T, et al. Regimen simplification to atzanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA 2006;296:806-14.
12. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173-80.
13. Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIVinfected subjects. J Infect Dis. 2005;191:825-9.
14. Dear Health Care Professional Letter. Clarification of risk factors for severe, life threatening and fatal heaptotoxicity with viramune (nevirapine), Boehringer Ingelheim, February 2004.
15. Kurowski M, Sternfield T, Sawyer A, et al. Pharmacokinetic and tolerability profile of twice daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers. HIV Med. 2003;4:94-100.
16. Jemsek J, Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment naïve, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. 11th Conference on Retroviruses and Opportunistic Infections; February 2004; San Francisco, CA.
17. Gallant JE, Rodriguea AE, Weinberg WG et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naïve subjects. J Infect Dis. 2005;192:1921-30.
18. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350:1850-61.
19. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society – USA panel. JAMA. 2006;296(7):827-43.
20. www.clinicaltrials.gov Accessed February 14, 2007.
21. Podzamczer D, Ferrer E, Gatell JM, et al. Early virologic failure with a combination of tenofovir, didanosine, and efavirenz. Antivir Ther. 2005;10:171-7.
22. Negredo E, Molto J, Burger D, at al. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable vial load. AIDS. 2004;18:459-63.
23. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001;344:984-996.
24. Moreno S, Hernandez B, Dronada F. Antiretroviral therapy in AIDS patients with tuberculosis. AIDS Rev. 2006;8:115-24.
25. Finch CK, Chrisman CR, Baciewicz AM, et al. Rifampin and rifabutin drug interactions: an update. Arch Intern Med. 2002;162:985-92.
26. Center for Disease Control. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV infected patients taking protease inhibitors or non-nucleoside reverse transcriptase inhibitors. Morb Mortal Wkly Rev. 2000;49:185-189.
27. Tribble MA, Gregg CR, Margolis DM, et al. Fatal ergotism induced by an HIV protease inhbitor. Headache. 2002;42:694-5.
28. Caballero-Granado FJ, Viciana P, Cordero E, at al. Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient. Antimicrob Agents Chemother. 1997;41:1207.
29. Johnson SR, Marion AA, Vrchoticky T, et al. Cushing syndrome with secondary adrenal insufficiency from concomittant therapy with ritonavir and fluticasone. J Pediatr. 2006;148:386-8.
30. Cushing’s syndrome in a patients treated with ritonavir/lopinavir and inhaled fluticasone. HIV Med. 2003;4:149-50.
31. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002;16:569-77.
32. Agarwala S, Gray K, Eley T. et al. Pharmacokinetic interaction between atazanavir and omeprazole in healthy subjects. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio De Janeiro, Brazil. July 24-27, 2005. Abstract WePe3.3C08.
33. Piscitelli, SC, Burnstein AH, Chaitt D, et al. Indinavir concentrations and St. John’s Wort. Lancet 2000;355:547-548.
34. Piscitelli SC, Burstein AH, Welden N, et al. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002;34:234-238.